Related Experiment Video
Updated: Jun 14, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
A comparative evaluation of medicated oils prepared using ayurvedic and modified processes
P Lahorkar1, K Ramitha, V Bansal
1Herbal Research Laboratory, Hindustan Unilever Research Centre, 64 Main Road, Whitefield, Bangalore-560 066, India.
Indian Journal of Pharmaceutical Sciences
|April 9, 2010
Summary
Ayurvedic medicated oils, prepared via Taila pak vidhi, undergo physicochemical changes during prolonged cooking. This study analyzes these transformations and the impact of process deviations on the final product quality.
Area of Science:
- Ayurvedic medicine
- Pharmacognosy
- Phytochemistry
Background:
- Medicated oils are integral to Ayurvedic treatments for various disorders.
- The traditional preparation method, Taila pak vidhi, involves prolonged cooking of sesame oil with herbal components.
Purpose of the Study:
- To investigate the physicochemical and chromatographic profiles of medicated oils prepared using Taila pak vidhi.
- To understand the role of each component during the preparation process.
- To analyze the impact of deviations from Ayurvedic procedures on the oil's profile.
Main Methods:
- Preparation of medicated oils following Ayurvedic principles (Taila pak vidhi).
- Physicochemical analysis of the prepared oils.
- Chromatographic profiling to assess chemical composition.
- Comparative analysis of oils prepared with altered procedures.
Main Results:
- Preliminary findings reveal significant physicochemical and chromatographic changes during the preparation of medicated oils.
- The study identified the contribution of different components to the observed changes.
- Deviations from prescribed methods resulted in altered profiles, indicating sensitivity to process parameters.
Conclusions:
- The Taila pak vidhi significantly modifies the physicochemical and chromatographic characteristics of medicated oils.
- Understanding these changes is crucial for ensuring the quality and efficacy of Ayurvedic oils.
- Adherence to traditional methods is important for consistent product profiles.
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...